Study
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer (NABUCCO Cohorts 1 and 2)
| Study ID | Alternative Stable ID | Type |
|---|---|---|
| EGAS00001004521 | Other |
Study Description
Study Datasets 9 datasets.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD00001006250 |
NABUCCO cohort 1 sequencing data. The dataset includes:
* Whole exome DNAseq pre-treatment on tumor samples (n=24) matched with blood samples (n=24)
* RNAseq pre-treatment on tumor samples (n=18)
* RNAseq post-treatment on tumor samples (n=18). Not all pre-treatment samples are linked with pre-treatment samples
* High coverage Whole exome DNAseq on pre-treatment tumor samples (n=3) matched with post-treatment metastasized lymph nodes isolated with laser microdissection (n=3)
* All samples are ... (Show More)
|
Illumina HiSeq 2500 | 69 |
| EGAD00001006850 |
Data from NABUCCO cohort 1 (NCT03387761). This dataset includes Whole exome DNA sequencing
on bladder tumor samples (n=24) matched with blood samples (n=24). The data is pre-treatment.
|
Illumina HiSeq 2500 | N/A |
| EGAD00001006851 |
Data from NABUCCO cohort 1 (NCT03387761). This dataset includes Tumor mutational burden (TMB) calculated on bladder tumor pre-treatment DNA sequencing data (n=24).
Details about the Tumor Mutational Burden calculation can be found on the Methods section from the Nature Medicine paper (https://doi.org/10.1038/s41591-020-1085-z)
|
N/A | |
| EGAD00001006852 |
Data from NABUCCO cohort 1 (NCT03387761). This dataset includes High coverage Whole exome DNA sequencing on pre-treatment bladder tumor samples (n=3) matched with post-treatment metastasised adjacent lymph nodes isolated with laser microdissection (n=3) for 3 unique patients
|
Illumina HiSeq 2500 | N/A |
| EGAD00001006853 |
Data from NABUCCO cohort 1 (NCT03387761). This dataset includes the Response labels used for the analysis of the data.
Details about the clinical definitions of Response can be found on the paper (https://doi.org/10.1038/s41591-020-1085-z)
|
N/A | |
| EGAD00001006854 |
Data from NABUCCO cohort 1 (NCT03387761). This dataset includes the Transcript read counts derived from the RNA sequencing data. The samples are pre-treatment (n=18) and post-treatment (n=18), and not all samples are paired.
The data processing pipeline can be found on the Methods section from the Nature Medicine paper (https://doi.org/10.1038/s41591-020-1085-z)
|
N/A | |
| EGAD00001006855 |
NABUCCO cohort 1 sequencing data. The dataset includes RNA sequencing pre-treatment on tumor samples (n=18) and RNA sequencing post-treatment on bladder tumor samples (n=18).
|
Illumina HiSeq 2500 | N/A |
| EGAD00001006856 |
Data from NABUCCO cohort 1 (NCT03387761). This dataset includes the pre-treatment PD-L1 staining on tumor samples (n=24).
Details about the PD-L1 staining can be found on the paper (https://doi.org/10.1038/s41591-020-1085-z)
|
N/A | |
| EGAD00001009864 |
Data from NABUCCO cohort 2 (NCT03387761). This dataset includes Whole exome DNA sequencing
on bladder tumor samples matched with blood samples for patients from NABUCCO Cohort 2 (Cohort 2A and Cohort 2B). The data is pre-treatment
|
Illumina NovaSeq 6000 | 59 |
Who archives the data?
